GenOMICC Study: The Royal Devon and Exeter Hospital was in the top 5 recruiting sites!

‘Whole genome sequencing reveals host factors underlying critical Covid-19’ is being published in Nature. (07/03/2022).

The full article at this link https://www.nature.com/articles/s41586-022-04576-6

Extract from the email:

This publication is the result of an extraordinary effort from so many under the most difficult of times, not least the patients and their families who consented to be part of the study. We still have a long journey ahead in trying to discover genetic associations affecting the progression of other critical illness, but this result shows what could be possible.

NIHR Clinical Research Network South West Peninsula – Sharing Celebration Video

Dear colleagues,

We are pleased to announce that video celebrating the successes of the research community across the South West Peninsula during the COVID-19 pandemic is now ready to watch on the NIHRTV YouTube channel.

The video features messages of thanks from some of our regional leaders as well as a personal message from Dr William van’t Hoff, NIHR CRN Chief Executive Officer. We also hear from research staff from across the three counties sharing their experiences and reflections on delivering research in a pandemic and an interview with a COVID-19 research participant.

We would like to thank you all again for your help in creating this video and for your continued efforts over the last two years – please take a moment individually and in your teams to reflect on everything you have helped achieve. You should all be so proud.

Michael Visick | Chief Operating Officer

NIHR Clinical Research Network South West Peninsula

Sanofi – BTKi MS and MG studies proposal – extract from email sent to PI & Team 12/04/2022

Royal Devon & Exeter have been leading the way recruiting patients to the Tolebrutinib studies including the MG EFC17262 and EFC16034 & EFC16645 MS studies across the UK and you have played a real pivotal part in UK recruitment.

Globally for the MG study, you have been the 2nd site to screen & randomise a patient and I know there is also a possible 2nd patient to pre-screen.

The MG study continues to face challenges globally and sites in other countries are seeing their SIV’s and activation slipping back due to different issues, therefore, globally the team are looking to the UK for help again.

We are also aware that you have over-recruited in the Gemini-2 study and nearly hit your recruitment target for Hercules study. However, as you may know, the recruitment is as a whole behind in the UK and the current international climate brings some uncertainty with regards to the data readouts so every patient counts!

MucAct COPD: What is the clinical effectiveness and cost-effectiveness of nebulised sodium chloride in patients with chronic obstructive pulmonary disease?

This is a community based study recruiting from primary care and the RD&E team are the only site at the moment.

 Patient 1 was recruited today (06/05/2022) – Great work team!

HemiSPAIRE: The effects of a modified muscle sparing posterior technique (SPAIRE) in hip hemiarthroplasty for displaced intracapsular fractures on post-operative function compared to a standard lateral approach; a randomised controlled trial:

HemiSPAIRE (RD&E Sponsored Study) Completed Recruitment: Consented 116 patients out of a total of 244 against the original site target of 30.

Excellent work from PEOC research team.